Original ArticleEvaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test
Introduction
Single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) is a common non-invasive form of cardiac testing, with imaging performed at rest before and after exercise. Patients who are unable to exercise to an adequate workload are considered to have an inadequate exercise stress test (EST); a pharmacological stress test can be used to increase myocardial perfusion and induce flow heterogeneity in those with obstructive coronary artery disease.1,2 There are a variety of pharmacological stress agents (PSAs) available, including regadenoson, adenosine, dipyridamole, and dobutamine. Regadenoson, adenosine, and dipyridamole are cardiac vasodilators, which dilate coronary vessels to increase blood velocity and flow rate in normal vessels and cause less of a response in stenotic vessels; they are the preferred agents for MPI.2 In clinical practice, the choice of agent depends on patient characteristics, the stress imaging techniques being performed, and provider preference.
Regadenoson, administered intravenously via a pre-filled syringe,3 is one of the most widely used PSAs.4 The EXERRT (EXErcise to Regadenoson in Recovery Trial) phase 3 trial showed that administration of regadenoson could occur during recovery from the inadequate EST at the same visit, rather than in a follow-up visit.5 These clinical trial findings suggest that the availability of regadenoson in a nuclear imaging center may affect real-world center practices related to the transition of patients from an inadequate EST to a PSA.
The objective of the current study was to evaluate how PSAs are currently used for patients during SPECT-MPI assessments following an inadequate EST and, more specifically, to (1) describe the protocol/practice implemented in nuclear imaging centers to convert patients from an inadequate EST to a PSA, and (2) assess resource use and time associated with the use of regadenoson compared to other PSAs.
Section snippets
Study Design
This was a cross-sectional study utilizing an online survey conducted between June and July 2019 to evaluate the use of PSAs during SPECT-MPI tests following an inadequate EST (the survey is 27 pages and is therefore not included). One-on-one telephone interviews with staff from nuclear imaging centers were conducted to facilitate survey development. The interviews were conducted with 6 staff members from different United States (US) nuclear imaging centers: 3 nuclear technicians/technologists,
Nuclear Imaging Staff and Center Characteristics
Of the 105 respondents, 50 completed the survey and were included in the analysis. Among the 55 respondents who did not complete the survey, 46 initiated but terminated the survey before completion for unknown reasons, 6 indicated they did not work closely with patients undergoing SPECT-MPI, 2 indicated they worked at centers that only did de novo pharmacological stress tests, and 1 did not initiate completion of the survey.
Characteristics of the nuclear imaging staff and centers are summarized
Discussion
Using an online survey, this study sought to characterize the resources, best practices, and time involved in PSA use during SPECT-MPI for patients with an inadequate EST from the perspective of nuclear imaging center staff. The findings show that regadenoson was the most commonly used and most preferred PSA for conversion after an inadequate EST. Regadenoson was used by centers because of convenience and a reasonable adverse event profile. The majority of patients using regadenoson were
New Knowledge Gained
This article provides new information on the efficiency of PSA use for patients converting from EST to PSA SPECT-MPI tests in real-world settings and confirms same-day conversion occurs for the majority of patients. Past research on the testing of conversion patients has been in clinical trial settings, focused on a subset of the available stress agents on the market, or been limited to perspectives from staff at single centers. This study compares real-world use of adenosine, dipyridamole, and
Acknowledgements
Medical writing/editorial support was provided by Laurie Orloski and Stephanie Bird from Xcenda and funded by the study sponsor.
Disclosures
H Yang, E. Faust, E. Gao, and S. Sethi are employed by Analysis Group, which provides consulting services to Astellas. R.M. Kristy and, J.R. Spalding are employees of and may have equity ownership in Astellas Pharma. T.M. Kitt and Y. Xu were employees of Astellas when the study was conducted, but have remained actively involved with the development of the manuscript.
Funding
References (11)
- et al.
ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers
J Nucl Cardiol.
(2016) - et al.
The EXERRT trial: “EXErcise to Regadenoson in Recovery Trial”: a phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol
J Nucl Cardiol.
(2017) - et al.
Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient
J Nucl Cardiol.
(2018) - Society of Nuclear Medicine and Molecular Imaging. Stress/rest myocardial perfusion imaging (MPI)....
- Lexiscan® (regadenoson) injection for intravenous use. Full prescribing information. 2018. Astellas Pharma US, Inc,...
Cited by (3)
Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: single photon emission computed tomography
2023, Journal of Nuclear CardiologyComparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
2023, Molecular Imaging and Radionuclide Therapy
Presented at Quality of Care and Outcomes Research 2020 Scientific Sessions, May 15–16, 2020, Reston, VA.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarizes the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.